1,861
Participants
Start Date
October 31, 2004
Primary Completion Date
July 31, 2007
Study Completion Date
May 31, 2012
cetuximab + cisplatin + vinorelbine
cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\^2 initial dose and 250mg/m\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
cisplatin + vinorelbine
cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
Research Site, Buenos Aires
Research Site, Córdoba
Research Site, Adelaide
Research Site, Melbourne
Research Site, Randwick
Research Site, Sydney
Research Site, Wodonga
Research Site, Vienna
Research Site, Brussels
Research Site, Charleroi
Research Site, Liège
Research Site, Porto Alegre
Research Site, São Paulo
Research Site, Pleven
Research Site, Sofia
Research Site, Stara Zagora
Research Site, Veliko Tarnovo
Research Site, Antofagasta
Research Site, Santiago
Research Site, Brno
Research Site, Ostrava
Research Site, Pilsen
Research Site, Prague
Research Site, Brest
Research Site, Caen
Research Site, Grenoble
Research Site, Marseille
Research Site, Paris
Research Site, Poitiers
Research Site, Rennes
Research Site, Rouen
Research Site, Strasbourg
Research Site, Augsburg
Research Site, Berlin
Research Site, Cologne
Research Site, Essen
Research Site, Freiburg im Breisgau
Research Site, Gauting
Research Site, Göttingen
Research Site, Großhansdorf
Research Site, Halle-Dölau
Research Site, Hamburg
Research Site, Heidelberg
Research Site, Löwenstein
Research Site, Magdeburg
Research Site, Mainz
Research Site, München
Research Site, Stralsund
Research Site, Wuppertal
Research Site, Honh Kong
Research Site, Budapest
Research Site, Nyiregyháza
Research Site, Székesfehérvár
Research Site, Szombathely
Research Site, Törökbálint
Research Site, Zalegerzeg-Pózva
Research Site, Dublin
Research Site, Bologna
Research Site, Carpi
Research Site, Milan
Research Site, Rome
Research Site, Rozzano-Milano
Research Site, Treviglio
Research Site, Mexico City
Research Site, Monterrey
Research Site, Amsterdam
Research Site, Nieuwegeln
Research Site, Zwolle
Research Site, Bydgoszcz
Research Site, Olsztyn
Research Site, Otwock
Research Site, Posnan
Research Site, Warsaw
Research Site, Wroclaw
Research Site, Moscow
Research Site, Saint Petersburg
Research Site, Singapore
Research Site, Banská Bystrica
Research Site, Bratislava
Research Site, Nitra-Zobor
Research Site, Poprad
Research Site, Seoul
Research Site, Barakaldo (Bilbao)
Research Site, Barcelona
Research Site, Donostia / San Sebastian
Research Site, Elche Alicante
Research Site, Granollers
Research Site, Madrid
Research Site, Pamplona
Research Site, Pontevedra
Research Site, Santander
Research Site, Terrassa
Research Site, Valencia
Research Site, Stockholm
Research Site, Uppsala
Research Site, Bern
Research Site, Thun
Research Site, Zurich
Research Site, Taipei
Research Site, Taipei
Research Site, Ankara
Research Site, Dnipropetrovsk
Research Site, Kharkiv
Research Site, Kyiv
Research Site, Lviv
Research Site, Poltava
Research Site, Sumy
Research Site, Ternopil
Research Site, Uzhhorod
Research Site, Aberdeen
Research Site, Bristol
Research Site, Edinburgh
Research Site, Leicester
Research Site, London
Research Site, Newcastle upon Tyne
Research Site, Poole
Research Site, Sutton
Research Site, Wolverhampton
Merck KGaA, Darmstadt, Germany
INDUSTRY